Drug Discovery

BenevolentAI, DNDi begin joint AI research project on dengue

BenevolentAI and Drugs for Neglected Disease initiative (DNDi) have commenced a joint AI research project to address dengue.

Biocytogen, CtM Biotech partner to develop new antibody drugs

Biocytogen Pharmaceuticals and CtM Biotech have entered into a collaboration agreement to co-develop TCR-mimic antibody-based multi-specific T cell engagers targeting intracellular tumor-associated antigens.

Asahi Kasei Medical agrees to buy Bionova Scientific

Asahi Kasei Medical’s US subsidiary has signed an agreement to acquire Bionova Scientific for an undisclosed amount.

Ardelyx amends license deal with Kyowa Kirin for tenapanor

Ardelyx and its Japanese collaboration partner Kyowa Kirin have amended their license agreement for tenapanor.

Harbour BioMed, AstraZeneca sign license deal for bispecific antibody

Biopharmaceutical firm Harbour BioMed (HBM) and AstraZeneca have entered into a global out-license agreement for CLDN18.2xCD3 bispecific antibody HBM7022.

FDA approves Junshi Biosciences’ IND application for anti-CD112R antibody

The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for Shanghai Junshi Biosciences’ anti-CD112R monoclonal antibody (TAB009/JS009) to treat advanced solid tumours.

Organon obtains license to Daré Bioscience’s Xaciato for bacterial vaginosis treatment

Women’s healthcare firm Organon has signed an agreement with Daré Bioscience for latter's Xaciato (clindamycin phosphate vaginal gel, 2%).

LifeMine secures funds to advance genomic drug discovery platform

LifeMine Therapeutics has raised $175m in a Series C financing to advance Avatar-Rx, its evolutionarily derived genomic drug discovery platform.

Affini-T Therapeutics secures funding to advance T cell therapies

Biotechnology firm Affini-T Therapeutics has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.